Tilray Launches ARX, Its First Premium Medical Cannabis Brand Developed And Cultivated In Germany

The introduction of ARX marks a significant step forward in the quality of medical cannabis available in Germany and reflects more than two years of development at the Aphria RX facility in Neumünster. Built through disciplined cultivation practices and deep operational expertise, ARX is grounded in the belief that patients and healthcare professionals require consistent, high-quality products.

Built on this foundation, ARX combines genetics sourced from the Broken Coast renowned library with cultivation expertise developed through years of premium cannabis production in Canada and executed with German precision. Produced and manufactured at Tilray Medical's Aphria RX facility, the brand is supported by the company's established German infrastructure, including national distribution through CC Pharma and 14U Pharma.

Rajnish Ohri, President, International, Tilray Brands, stated: "The launch of ARX marks an important milestone for Tilray in Germany as our first premium medical cannabis brand developed and cultivated in-market. Germany continues to lead the evolution of medical cannabis in Europe, and we are committed to supporting that growth with locally produced, high-quality products that meet the needs of patients and healthcare professionals. With ARX, we are strengthening our position in this critical market while advancing consistency, supply reliability, and long-term patient access."

Raising the Standard of Commitment to Patients in Germany

ARX begins with a strong foundation. All strains are sourced exclusively from Broken Coast's genetic library. Since 2014, Broken Coast has been recognized as one of Canada's original Licensed Producers of medical cannabis and remains a leading producer of premium cannabis products, with deep expertise in strain selection and phenotyping.

ARX is produced under strict EU-GMP standards at the Aphria RX facility in Neumünster. Drawing on Broken Coast's cultivation expertise, the production process is designed to support consistency and product integrity. Individual, climate-controlled grow rooms allow each cultivar to be developed under tailored conditions, while continuous monitoring and real-time adjustments help maintain quality throughout cultivation. This approach reflects a core belief: patients deserve consistent, high-quality products. Fully integrated, in-house operations reduce handling and delays, helping support product consistency without the need for irradiation.